Amazon Surpasses Walmart In Quarterly Revenue
For the first time ever, e-commerce giant Amazon (AMZN) has surpassed discount retailer Walmart (WMT) in terms of quarterly revenue generated. Amazon reported fourth-quarter 2024 revenue of $187.80 billion U.S., which beat Walmart’s sales for the same period that totaled $180.50 billion U.S. Since 2012, Walmart has been the top revenue generator among publicly listed U.S. companies, a title it won after overtaking oil giant Exxon Mobil (XOM) in terms of sales. While Walmart may have lost its crown when it comes to quarterly sales, the company still leads in annual sales. Walmart has forecast total sales this year of $708.70 billion U.S., while Amazon’s full-year revenue for 2025 is projected at $700.80 billion U.S. Amazon’s e-commerce business remains its biggest revenue generator, but its sales are also being fueled by its growing cloud computing, advertising and streaming businesses. Amazon Web Services (AWS), the company’s cloud unit, accounted for nearly 20% of total revenue achieved in 2024.Meanwhile, Walmart’s discount pricing continues to attract price-conscious consumers. The retailer has also launched an advertising business and a loyalty program called “Walmart+.” The stock of Amazon has risen 32% over the last 12 months to trade at $222.88 U.S. per share.Walmart’s stock has gained 68% in the past year to trade at $97.21 U.S. a share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


